The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.

Baku Medical Plaza Baku Azerbaijan

Cantacuzino National Medico Military Institute for Research Development Bucharest Romania

Central Research Institute of Epidemiology Moscow Russia

Eskisehir Osmangazi University Eskisehir Turkey

Institute for Public Health Sombor Serbia

Institute of Health Carlos 3 Madrid Spain

Kazakh National Medical University Almaty Kazakhstan

Meningitis Research Foundation Bristol UK

Meningococcal Reference Unit Public Health England Manchester Royal Infirmary Manchester M13 9WZ UK

National Center for Disease Control and Public Health Tbilisi Georgia

National Institute of Public Health Prague Czechia

National Public Health Center Budapest Hungary

National Reference Centre for Bacterial Meningitis National Medicines Institute Warsaw Poland

National Reference Centre for Meningococci Institute Pasteur Paris France

Norwegian Institute of Public Health Oslo Norway

Republican Research and Practical Center for Epidemiology and Microbiology Minsk Belarus

Riga East University Hospital Riga Latvia

Scientific and Production Association Preventive Medicine Bishkek Kyrgyzstan

The Centre for Disease Prevention and Control of Latvia Riga Latvia

University Hospital for Infectious Diseases Zagreb Croatia

000      

00000naa a2200000 a 4500

001      

bmc20025441

003      

CZ-PrNML

005      

20201222153918.0

007      

ta

008      

201125s2019 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jinf.2019.10.018 $2 doi

035    __

$a (PubMed)31682877

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Bai, Xilian $u Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester M13 9WZ, UK. Electronic address: Xilian.Bai@phe.gov.uk.

245    10

$a Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe / $c X. Bai, R. Borrow, S. Bukovski, DA. Caugant, D. Culic, S. Delic, EC. Dinleyici, M. Eloshvili, T. Erdősi, J. Galajeva, P. Křížová, J. Lucidarme, K. Mironov, Z. Nurmatov, M. Pana, E. Rahimov, L. Savrasova, A. Skoczyńska, V. Smith, MK. Taha, L. Titov, J. Vázquez, L. Yeraliyeva,

520    9_

$a The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.

650    _2

$a přenašečství $x epidemiologie $x mikrobiologie $x prevence a kontrola $7 D002353

650    _2

$a kontrola infekčních nemocí $x organizace a řízení $7 D003140

650    12

$a epidemický výskyt choroby $7 D004196

650    _2

$a přenos infekční nemoci $x prevence a kontrola $7 D018562

650    _2

$a lidé $7 D006801

650    _2

$a incidence $7 D015994

650    _2

$a meningokokové infekce $x epidemiologie $x mikrobiologie $x prevence a kontrola $7 D008589

650    _2

$a meningokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022401

650    _2

$a Neisseria meningitidis $x klasifikace $x izolace a purifikace $7 D009345

650    _2

$a séroskupina $7 D065288

651    _2

$a východní Evropa $x epidemiologie $7 D005061

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Borrow, Ray $u Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester M13 9WZ, UK. Electronic address: Ray.Borrow@phe.gov.uk.

700    1_

$a Bukovski, Suzana $u University Hospital for Infectious Diseases, Zagreb, Croatia. Electronic address: sbukovski@bfm.hr.

700    1_

$a Caugant, Dominique A $u Norwegian Institute of Public Health, Oslo, Norway. Electronic address: dominique.caugant@fhi.no.

700    1_

$a Culic, Davor $u Institute for Public Health, Sombor, Serbia. Electronic address: mikrobiologija@zzjzsombor.org.

700    1_

$a Delic, Snezana $u Institute for Public Health, Sombor, Serbia. Electronic address: mikrobiologija@zzjzsombor.org.

700    1_

$a Dinleyici, Ener Cagri $u Eskisehir Osmangazi University, Eskisehir, Turkey.

700    1_

$a Eloshvili, Medeia $u National Center for Disease Control & Public Health, Tbilisi, Georgia. Electronic address: m.eloshvili@ncdc.ge.

700    1_

$a Erdősi, Tímea $u National Public Health Center, Budapest, Hungary. Electronic address: erdosi.timea@nnk.gov.hu.

700    1_

$a Galajeva, Jelena $u Riga East University Hospital, Riga, Latvia. Electronic address: jelena.galajeva@aslimnica.lv.

700    1_

$a Křížová, Pavla $u National Institute of Public Health, Prague, Czechia. Electronic address: pavla.krizova@szu.cz.

700    1_

$a Lucidarme, Jay $u Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester M13 9WZ, UK. Electronic address: Jay.Lucidarme@phe.gov.uk.

700    1_

$a Mironov, Konstantin $u Central Research Institute of Epidemiology, Moscow, Russia. Electronic address: mironov@pcr.ru.

700    1_

$a Nurmatov, Zuridin $u Scientific and Production Association "Preventive Medicine", Bishkek, Kyrgyzstan. Electronic address: z.nurmatov@mail.ru.

700    1_

$a Pana, Marina $u Cantacuzino National Medico Military Institute for Research Development, Bucharest, Romania.

700    1_

$a Rahimov, Erkin $u Baku Medical Plaza, Baku, Azerbaijan.

700    1_

$a Savrasova, Larisa $u The Centre for Disease Prevention and Control of Latvia, Riga, Latvia. Electronic address: larisa.savrasova@spkc.gov.lv.

700    1_

$a Skoczyńska, Anna $u National Reference Centre for Bacterial Meningitis, National Medicines Institute, Warsaw, Poland. Electronic address: a.skoczynska@nil.gov.pl.

700    1_

$a Smith, Vinny $u Meningitis Research Foundation, Bristol, UK. Electronic address: vinnys@meningitis.org.

700    1_

$a Taha, Muhamed-Kheir $u National Reference Centre for Meningococci, Institute Pasteur, Paris, France. Electronic address: muhamed-kheir.taha@pasteur.fr.

700    1_

$a Titov, Leonid $u Republican Research & Practical Center for Epidemiology & Microbiology, Minsk, Belarus. Electronic address: leonidtitov@tut.by.

700    1_

$a Vázquez, Julio $u Institute of Health Carlos III, Madrid, Spain. Electronic address: jvazquez@isciii.es.

700    1_

$a Yeraliyeva, Lyazzat $u Kazakh National Medical University, Almaty, Kazakhstan. Electronic address: l.yeraliyeva@gmail.com.

773    0_

$w MED00002744 $t The Journal of infection $x 1532-2742 $g Roč. 79, č. 6 (2019), s. 528-541

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31682877 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20201222153914 $b ABA008

999    __

$a ok $b bmc $g 1599586 $s 1116127

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 79 $c 6 $d 528-541 $e 20191101 $i 1532-2742 $m The Journal of infection $n J Infect $x MED00002744

LZP    __

$a Pubmed-20201125